Pharmacology of dopaminergic neurotransmission

Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy: Third Edition

Volumn , Issue , 2012, Pages 440-480

  Standaert, David G ^a,b   Walsh, Ryan R ^a,c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA HOSPITAL   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85050915070     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (6)

1. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366-375. (A classic article that describes the concept of "direct" and "indirect" pathways.)
2. Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 2006;7:306-318. (A review of the rapidly evolving genetics of Parkinson's disease.)
3. Kellendonk C, Simpson EH, Polan HJ, et al. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 2006;49:603-615. (A new mouse model for schizophrenia suggesting a role for D2 receptors in cognitive impairment.)
4. Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006;59:591-596. (A review that emphasizes the many aspects of Parkinson's disease beyond the motor abnormalities.)
5. Spooren W, Riemer C, Meltzer H. NK3 receptor antagonists: the next generation of antipsychotics? Nat Rev Drug Discov 2005;4:967-975. (Discusses pathophysiologic basis of potential antipsychotic agents.)
6. Suchowersky O, Reich S, Perlmutter J, et al. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:968-975. (This "parameter," as well as several others published in the same issue, represents the product of a careful review of the evidence for the effectiveness of various treatments for Parkinson's disease.)